Idibellhospital Universitari Of Bellvitge

LHospitalet, Spain

Idibellhospital Universitari Of Bellvitge

LHospitalet, Spain
SEARCH FILTERS
Time filter
Source Type

Ripoll E.,Idibellhospital Universitari Of Bellvitge | Merino A.,Idibellhospital Universitari Of Bellvitge | Goma M.,Hospital Universitari Of Bellvitge | Aran J.M.,LHospitalet | And 7 more authors.
PLoS ONE | Year: 2013

Lupus nephritis (LN) is an autoimmune disorder in which co-stimulatory signals have been involved. Here we tested a cholesterol-conjugated-anti-CD40-siRNA in dendritic cells (DC) in vitro and in a model of LPS to check its potency and tissue distribution. Then, we report the effects of Chol-siRNA in an experimental model of mice with established lupus nephritis. Our in vitro studies in DC show a 100%intracellular delivery of Chol-siRNA, with a significant reduction in CD40 after LPS stimuli. In vivo in ICR mice, the CD40-mRNA suppressive effects of our Chol-siRNA on renal tissue were remarkably sustained over a 5 days after a single preliminary dose of Chol-siRNA. The intra-peritoneal administration of Chol-siRNA to NZB/WF1 mice resulted in a reduction of anti-DNA antibody titers, and histopathological renal scores as compared to untreated animals. The higher dose of Chol-siRNA prevented the progression of proteinuria as effectively as cyclophosphamide, whereas the lower dose was as effective as CTLA4. Chol-siRNA markedly reduced insterstitialCD3+ and plasma cell infiltrates as well as glomerular deposits of IgG and C3. Circulating soluble CD40 and activated splenic lymphocyte subsets were also strikingly reduced by Chol-siRNA. Our data show the potency of our compound for the therapeutic use of anti-CD40-siRNA in human LN and other autoimmune disorders. © 2013 Ripoll et al.

Loading Idibellhospital Universitari Of Bellvitge collaborators
Loading Idibellhospital Universitari Of Bellvitge collaborators